Navigation Links
Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Adrian Schwarzer, MD, Ph.D. to its Scientific Advisory Committee
Date:12/23/2013

MILLBROOK, N.Y., Dec. 23, 2013 /PRNewswire/ -- Dr. Schwarzer is affiliated with Hannover Medical School in Hannover, Germany at the Institute of Experimental Hematology and resident in the Department of Hematology, Oncology and Stem Cell Transplantation. Dr. Schwarzer has an MD in Immunology and Ph.D. in Molecular Medicine/Biochemistry. He is currently engaged in investigating the role of cap dependent translation in acute lymphoblastic leukemias with a special focus on T-ALL.

We at Egenix are delighted to have Dr. Schwarzer aboard and feel confident that he will make significant contributions to the advancement of science and medicine.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated be a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com

 


'/>"/>
SOURCE Egenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. KaloBios Appoints Donald R. Joseph as Chief Legal Officer
2. TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimers Disease Research, His Third Endowed Chair
3. Imaging Contract-Research Pioneer, Donald P. Rosen, MD, Named CEO of ACR Image Metrix™
4. Gregory Frank Named President of Two Leading Immunology Biotech Companies; Pure Protein and Pure MHC
5. Cargill’s Dielectric Transformer Oil Made from Natural Esters Wins Presidential Green Chemistry Award
6. The Leukemia & Lymphoma Societys "A Tribute to Jackie" Photo Collection Part of Auction Commemorating the 50th Anniversary of President Kennedys Assassination
7. TrialNetworks Co-founder and Chairman Vivek Murthy, MD, MBA, Nominated by President Barack Obama as Surgeon General of the United States of America
8. ISPE Names Dr. Thomas Zimmer as Vice President of European Operations
9. Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.
10. Sigma-Aldrich Corporation Delcares Quarterly Dividend Of $0.215 Per Share And Announces Election Of New Vice President And Treasurer
11. Gentris Corporation Partners with BioFortis, Announces New Vice President of Information Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)...  In the pharmaceutical industry the medical affairs function ... activities including the identification and engagement of key thought ... high in the oncology therapeutic area where most treating ... Role of Medical Affairs in Oncology Launch Excellence ." ... find better ways to utilize medical affairs to develop ...
(Date:2/4/2016)... New FDA action date of July 22, 2016   ... 22, 2016   --> - New FDA ... - Lifitegrast has the potential to be the only product approved ... and symptoms of dry eye disease in adults --> - ... the U.S. in the past decade indicated for the treatment of signs and ...
(Date:2/4/2016)... 2016  CytoSorbents Corporation (NASDAQ: CTSO ), ... CytoSorb® blood filter to treat deadly inflammation in ... announced that CEO Dr. Phillip Chan , ... Group,s 2016 Disruptive Growth & Healthcare Conference, providing ... Conference Presentation Details: Where: Convene Conference ...
(Date:2/4/2016)... 2016 Sinovac Biotech Ltd. ("Sinovac" or the ... biopharmaceutical products in China , today ... directors received on February 4, 2016 a preliminary non-binding ... comprised of PKU V-Ming ( Shanghai ) ... Qianhai Development ( Shenzhen ) Fund Management ...
Breaking Biology Technology:
(Date:1/11/2016)... , Jan. 11, 2016  higi, the ... nearly 10,000 retail locations, web and mobile, today ... $40 million from existing investors. ... be devoted to further innovate higi,s health platform ... and web portal – including expanding services and ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC Research ... for biometric technologies and devices, identifying newer markets and ... various types of biometric devices. Includes forecast from 2015 ... Identify newer markets and explore the expansion of the ... Examine each type of biometric technology, determine its current ...
(Date:1/6/2016)... 6, 2016  Varam Capital, a provider of micro-finance ... to deliver advanced authentication solutions to their clients. Varam ... poor. A loan of a few thousand rupees may ... the ability to purchase livestock or equipment for a ... stock for a local store. ...
Breaking Biology News(10 mins):